Therefore, targeting these changes may allow for a promising therapeutic strategy to overcome acquired drug resistance to HER2-targeted and CDK4/6-targeted therapies in HER2+ and ER+ breast cancers, respectively. The gene discussed is ESR1; the disease is breast carcinoma.